Independent · evidence-anchored—Reviewed by the GLPHelper Medical Team
EN·ES·For Providers ↗
glp·helper
Find a Provider →
glphelper.com/mounjaro/nevada
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® Providers &
Prescriptions in Nevada

Verified Mounjaro providers across Nevada. Checked against the NPI registry, sorted by waitlist — not by who pays us.[7]

state providers
44
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25–$1,150
monthly
01 / Find
stateNEVADA
Search 44 results →
Popular →Las Vegas
Filters: insurance, telehealth, waitlist, dose
§ 01Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults — same molecule as Ozempic, higher dose.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist — it activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8–2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy
§ 02Clinical evidence
STEP 1–4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8–2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
§ 04Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%) — more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12–24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12–19%
mild
More frequent during dose escalation
Vomiting
5–13%
mild
Reduced by slower titration
Constipation
6–17%
mild
Decreased appetite
5–11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1–2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 05Cost & coverage — published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash — Mounjaro (no insurance)
$1,000 – $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 – $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 – $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
§ 06Provider directory — Nevada
17 of 17 shown

Find a Mounjaro provider in Nevada.

Every entry is checked against the NPI registry and the Nevada medical board. Listings are ordered by current waitlist — the provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Nevada city · /mounjaro/nevada/{city}
Las Vegas
36.17°N
31 →
§ 07Frequently asked — Mounjaro in Nevada

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources — never marketing copy.

They are the same molecule — tirzepatide, made by Eli Lilly — with different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]